As CA19–9 and AFP are widely used biomarkers for diagnosing ICC and HCC, respectively, the combined use of CA19–9 and AFP levels is prevalent in distinguishing ICC from HCC in clinical practice (7, 16, 20), and we constructed this model (Model 2) in our study. Here, AFP is linked to intrahepatic cholangiocarcinoma.